A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma
Hoosier Cancer Research Network
Hoosier Cancer Research Network
National Cancer Institute (NCI)
University of Southern California
AHS Cancer Control Alberta
Eastern Cooperative Oncology Group
University of Miami
Stanford University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)